MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
Gilead Sciences Operating Cycle 2011-2026 | GILD
Annual Operating Cycle Gilead Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 160 | 160 | 156 | 163 | 154 | 167 | 130 | 116 | 121 | 190 | 244 | 202 | 331 | 324 | 324 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 331 | 116 | 196 |
Quarterly Operating Cycle Gilead Sciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 163 | 168 | 163 | - | 169 | 176 | 171 | - | 154 | 160 | 165 | - | 152 | 152 | 157 | - | 182 | 176 | 179 | 60.1 | 202 | 231 | 192 | 55.6 | 140 | 142 | 142 | 52.4 | 123 | 116 | 138 | 59.1 | 125 | 114 | 58.7 | 56.3 | 54.9 | 53 | 60.7 | 62.8 | 64.4 | 64.8 | 63 | 57.8 | 70 | 64.7 | 62.2 | 62.6 | 68.9 | 69.2 | 69.4 | 61.8 | 65.9 | 66.5 | 74 | 80.9 | 83.9 | 83.3 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 231 | 52.4 | 110 |
Operating Cycle of other stocks in the Biotechnology industry
| Issuer | Operating Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
245 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B |  USA |
 |
Aptorum Group Limited
APM
|
4.89 | $ 0.89 | - | $ 6.54 M | China |
 |
ACADIA Pharmaceuticals
ACAD
|
332 | $ 22.35 | 0.68 % | $ 3.7 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
32 | - | -1.52 % | $ 24.7 M | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
115 | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Aquestive Therapeutics
AQST
|
223 | $ 4.08 | 0.74 % | $ 436 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
59 | - | 17.91 % | $ 11.1 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
291 | $ 22.65 | 1.25 % | $ 2.88 B | USA |
 |
Edesa Biotech
EDSA
|
97.1 | $ 16.23 | 2.08 % | $ 51.9 M | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
129 | $ 1.42 | 0.71 % | $ 378 M | Britain |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M |  Israel |
 |
AstraZeneca PLC
AZN
|
206 | - | - | $ 96.9 B | Britain |
 |
Evogene Ltd.
EVGN
|
30 | $ 0.79 | 4.79 % | $ 27.9 M | Israel |
 |
BioDelivery Sciences International
BDSI
|
436 | - | -4.8 % | $ 255 M | USA |
 |
Exelixis
EXEL
|
140 | $ 45.0 | 0.69 % | $ 12.2 B | USA |
 |
BeiGene, Ltd.
BGNE
|
52.6 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Завод ДИОД
DIOD
|
64.6 | - | - | - | Russia |